Meanwhile in biotechEvaxion reports durable responses; Novartis halts kidney trial; AstraZeneca signs AI dealBeyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers cancer vaccine follow-up, changes to kidney and obesity trials, and two developments in … more ➔
M&AAmbrose expands rare disease pipeline with €161M AM-Pharma acquisitionBritish rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrec … more ➔
licensing$15 billion deal: Roche bets on China — and questions Germany’s futureThe Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential milestone payments exceeding $15 billion. The deal comes amid mixed developments: … more ➔
M&AMerck to buy siRNA specialist Silence Therapeutics for $1.3 billionMerck KGaA is acquiring British biotech company Silence Therapeutics for $1.3 billion. The main value driver is an siRNA candidate for polycythemia vera. But the research platform and Berlin site are … more ➔
Venture CapitalFresenius Ventures’ managing director: Europe has the investors. It needs the capital.Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director of Fresenius Ventures, to share his perspective in the Autumn issue of … more ➔
clinical dataOSE reports positive Phase 2 data, but questions remainFrench biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial. However, … more ➔
RegulatoryCHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launchEach month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European patients — and which should not. Here are eight decisions from its October … more ➔
fundraisingNouscom raises €120M to advance cancer prevention vaccineSwiss biotech Nouscom has raised €120 million in an oversubscribed Series D financing to advance NOUS-209, an experimental cancer vaccine designed to prevent tumors in people with Lynch syndrome, into … more ➔
clinical dataOsivax misses Phase 2b flu vaccine endpoint, shifts focus to combinationsFrench-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, which achieved a nonsignificant efficacy estimate of 24% against a predefined … more ➔
AppointmentsEvotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a swift scientific leadership change … more ➔
